Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.066 CHF | +4.10% | +21.77% | +60.98% |
05-01 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
04-17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+60.98% | 4.73M | |
-2.35% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+54.94% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+6.52% | 9.03B |
- Stock Market
- Equities
- POLN Stock
- News Spexis AG
- Spexis Strikes Clinical Trial Partnership to Develop Lung Infection Drug ColiFin